SC 13D/A





Washington, D.C. 20549




Under the Securities Exchange Act of 1934

(Amendment No. 1)*



Carisma Therapeutics Inc.

(Name of Issuer)

Common Stock, par value $0.001

(Title of Class of Securities)

14216R 101

(CUSIP Number)

Trustees of the University of Pennsylvania

2929 Walnut Street, Suite 300

Philadelphia, PA 19104

(215) 898-1903

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

September 15, 2023

(Date of Event Which Requires Filing of This Statement)



If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.  ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




CUSIP No. 428304307



  Names of Reporting Persons


  Trustees of the University of Pennsylvania


  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐



  SEC Use Only



  Source of Funds (See Instructions)




  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)




  Citizenship or Place of Organization













  Sole Voting Power




  Shared Voting Power




  Sole Dispositive Power




  Shared Dispositive Power




  Aggregate Amount Beneficially Owned by Each Reporting Person




  Check if the Aggregate Amount in Row (11) Excludes Certain Shares




  Percent of Class Represented by Amount in Row (11)




  Type of Reporting Person





As more fully described in the responses to Items 3 through 6 of this Schedule 13D, based on approximately 40,356,806 shares of Common Stock (as defined below) of the Issuer (as defined below) outstanding as of November 6, 2023.


This Amendment No. 1 (“Amendment”) to Schedule 13D is filed by The Trustees of the University of Pennsylvania (the “Reporting Person”) with respect to the common stock, par value $0.001 (“Common Stock”) of Carisma Therapeutics, Inc. a Delaware corporation (the “Issuer”), originally filed on behalf of the Reporting Person with the United States Securities and Exchange Commission (the “SEC”) on March 17, 2023 (the “Original Schedule 13D”) to amend and restate the disclosures provided in Items 5(a) – (c) of the Original Schedule 13D. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Original Schedule 13D.

Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Original Schedule 13D.

Item 5. Interest in Securities of the Issuer.

The disclosures provided in Item 5(a) – (c) of the Original Schedule 13D are hereby amended and restated in their entirety as follows:

(a) and (b) Items 7 to 11 of the cover pages of this Schedule 13D are incorporated herein by reference.

(c) The transactions effected by the Reporting Person in respect of Common Stock since the most recent filing of the Reporting Person on Schedule 13D are set forth on the below table. All transactions below were effected by the Reporting Person in open market transactions at prevailing markets prices.


Transaction Date


Price Per Share


Number of Shares



9/13/2023    5.0000    2,762    Sale
9/13/2023    4.8242    19,884    Sale
9/14/2023    4.7232    23,043    Sale
9/15/2023    4.8628    43,683    Sale
9/15/2023    5.0133    600    Sale
9/18/2023    5.0000    200    Sale
9/18/2023    4.8095    29,462    Sale
9/19/2023    4.6000    35,380    Sale
9/20/2023    4.5610    32,801    Sale
9/21/2023    3.9681    61,003    Sale
9/22/2023    3.9459    38,669    Sale
9/22/2023    4.0700    80    Sale
9/25/2023    4.0992    23,908    Sale
9/26/2023    4.2474    13,741    Sale
9/27/2023    4.4373    41,186    Sale
9/28/2023    4.3725    27,254    Sale
9/29/2023    4.2700    29,312    Sale
10/2/2023    4.2569    11,299    Sale
10/9/2023    4.3295    16,382    Sale
10/10/2023    4.3141    22,530    Sale
10/11/2023    4.1729    82,680    Sale
10/12/2023    3.5780    57,745    Sale
10/13/2023    3.4588    57,547    Sale
10/16/2023    3.3783    38,638    Sale
10/17/2023    3.3855    42,968    Sale
10/18/2023    3.0518    42,889    Sale
10/19/2023    2.9741    28,615    Sale
10/20/2023    2.8496    25,963    Sale
10/23/2023    2.7788    40,794    Sale
10/24/2023    2.8627    27,662    Sale
10/25/2023    2.7829    12,025    Sale


After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

Date: January 26, 2024





/s/ Margaret Heer



Margaret Heer



Associate Treasurer